Literature DB >> 17031554

Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models.

Shin-ichiro Sugiyama1, Yoji Yamashita, Toshio Kikuchi, Ryuta Saito, Toshihiro Kumabe, Teiji Tominaga.   

Abstract

Convection-enhanced delivery (CED) is a local infusion technique, which delivers chemotherapeutic agents directly to the central nervous system, circumventing the blood-brain barrier and reducing systemic side effects. CED distribution is significantly increased if the infusate is hydrophilic. This study evaluated the safety and efficacy of CED of nimustine hydrochloride: 3-[(4-amino-2-methyl-5-pyrimidinyl) methyl]-1-(2-chloroethyl)-1-nitrosourea hydrochloride (ACNU), a hydrophilic nitrosourea, in rat 9 L: brain tumor models. The local neurotoxicity of ACNU delivered via CED was examined in normal rat brains, and the maximum tolerated dose (MTD) was estimated at 0.02 mg/rat. CED of ACNU at the MTD produced significantly longer survival time than systemic administration (P < 0.05, log-rank test). Long-term survival (80 days) and eradication of the tumor occurred only in the CED-treated rats. The tissue concentration of ACNU was measured by high-performance liquid chromatography, which revealed that CED of ACNU at the dose of 100-fold less total drug than intravenous injection carried almost equivalent concentrations of ACNU into rat brain tissue. CED of hydrophilic ACNU is a promising strategy for treating brain tumors.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17031554     DOI: 10.1007/s11060-006-9247-5

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  28 in total

Review 1.  The blood-brain and blood-tumor barriers: a review of strategies for increasing drug delivery.

Authors:  D R Groothuis
Journal:  Neuro Oncol       Date:  2000-01       Impact factor: 12.300

2.  Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.

Authors:  Ryuta Saito; Michal T Krauze; Charles O Noble; Daryl C Drummond; Dmitri B Kirpotin; Mitchel S Berger; John W Park; Krystof S Bankiewicz
Journal:  Neuro Oncol       Date:  2006-05-24       Impact factor: 12.300

3.  Nitrosourea pharmacodynamics in relation to the central nervous system.

Authors:  M D Walker; J Hilton
Journal:  Cancer Treat Rep       Date:  1976-06

4.  [Chemotherapy of malignant brain tumor by a water-soluble anti-tumor nitrosourea, ACNU (author's transl)].

Authors:  T Mori; K Mineura; R Katakura
Journal:  Neurol Med Chir (Tokyo)       Date:  1979-12       Impact factor: 1.742

5.  A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma.

Authors:  Manfred Westphal; Dana C Hilt; Enoch Bortey; Patrick Delavault; Robert Olivares; Peter C Warnke; Ian R Whittle; Juha Jääskeläinen; Zvi Ram
Journal:  Neuro Oncol       Date:  2003-04       Impact factor: 12.300

6.  Convection-enhanced delivery of macromolecules in the brain.

Authors:  R H Bobo; D W Laske; A Akbasak; P F Morrison; R L Dedrick; E H Oldfield
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-15       Impact factor: 11.205

7.  Intracerebral clysis in a rat glioma model.

Authors:  J N Bruce; A Falavigna; J P Johnson; J S Hall; B D Birch; J T Yoon; E X Wu; R L Fine; A T Parsa
Journal:  Neurosurgery       Date:  2000-03       Impact factor: 4.654

Review 8.  Intratumoral chemotherapy.

Authors:  K A Walter; R J Tamargo; A Olivi; P C Burger; H Brem
Journal:  Neurosurgery       Date:  1995-12       Impact factor: 4.654

9.  Neuro-Oncology Working Group 01 trial of nimustine plus teniposide versus nimustine plus cytarabine chemotherapy in addition to involved-field radiotherapy in the first-line treatment of malignant glioma.

Authors:  Michael Weller; Bettina Müller; Rainer Koch; Michael Bamberg; Peter Krauseneck
Journal:  J Clin Oncol       Date:  2003-09-01       Impact factor: 44.544

10.  Ventriculolumber perfusion of 3-[(4-amino-2-methyl-5-pyrimidinyl)-methyl]-1-(2-chloroethyl-1-nitrosou rea hydrochloride for subarachnoid dissemination of gliomas.

Authors:  Y Ushio; M Kochi; I Kitamura; J Kuratsu
Journal:  J Neurooncol       Date:  1998 Jun-Jul       Impact factor: 4.130

View more
  5 in total

1.  Effects of chemotherapeutics on organotypic corticostriatal slice cultures identified by a panel of fluorescent and immunohistochemical markers.

Authors:  Annette Nørregaard; Stine Skov Jensen; Jesper Kolenda; Charlotte Aaberg-Jessen; Karina Garnier Christensen; Poul Henning Jensen; Henrik Daa Schrøder; Bjarne Winther Kristensen
Journal:  Neurotox Res       Date:  2011-12-28       Impact factor: 3.911

2.  Efficacy of interstitial continuous vincristine infusion in a bioluminescent rodent intracranial tumor model.

Authors:  Guifa Xi; Barbara Mania-Farnell; Veena Rajaram; Chandra S Mayanil; Marcelo B Soares; Tadanori Tomita; Stewart Goldman
Journal:  J Neurooncol       Date:  2011-08-14       Impact factor: 4.130

3.  Interstitial continuous infusion therapy in a malignant glioma model in rats.

Authors:  Yuichi Tange; Akihide Kondo; Merrill J Egorin; Barbara Mania-Farnell; Georgy M Daneriallis; Hiromichi Nakazaki; Simone T Sredni; Veena Rajaram; Stewart Goldman; Marcelo B Soares; Tadanori Tomita
Journal:  Childs Nerv Syst       Date:  2009-02-11       Impact factor: 1.475

4.  Influence of the Expression Level of O6-Alkylguanine-DNA Alkyltransferase on the Formation of DNA Interstrand Crosslinks Induced by Chloroethylnitrosoureas in Cells: A Quantitation Using High-Performance Liquid Chromatography-Mass Spectrometry.

Authors:  Lili Li; Sisi Li; Guohui Sun; Ruizeng Peng; Lijiao Zhao; Rugang Zhong
Journal:  PLoS One       Date:  2015-03-23       Impact factor: 3.240

5.  Phase I trial of convection-enhanced delivery of nimustine hydrochloride (ACNU) for brainstem recurrent glioma.

Authors:  Ryuta Saito; Masayuki Kanamori; Yukihiko Sonoda; Yoji Yamashita; Kenichi Nagamatsu; Takaki Murata; Shunji Mugikura; Toshihiro Kumabe; Eva Wembacher-Schröder; Rowena Thomson; Teiji Tominaga
Journal:  Neurooncol Adv       Date:  2020-03-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.